Qing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qing Li has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Herren Wu
Department of Antibody Discovery & Protein Engineering, AstraZeneca plc, Gaithersburg, MD, United States of America
5 shared publicationsKevin L. Allen
4 shared publicationsM. Jack Borrok
4 shared publicationsPing Tsui
Department of Antibody Discovery & Protein Engineering, AstraZeneca plc, Gaithersburg, MD, United States of America
4 shared publicationsKeith W. Rickert
3 shared publicationsNorman Peterson
2 shared publications
Latest Publications
- 5 April 2023
- Published by Elsevier in Biotechnology Advances
- Vol. 65, 108143
Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis
- 5 April 2023
- Published by Elsevier in Biotechnology Advances
- Vol. 65, 108143
Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis
- Open Access
- 4 June 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (6) , e0234268
Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models
Annexin A1 (anxA1) is an immunomodulatory protein that has been proposed as a tumor vascular target for antitumor biologic agents, yet to date the vascular expression of anxA1 in specific tumor indications has not been systematically assessed. Attempts to evaluate vascular anxA1 expression by immunohistochemistry are complicated by a lack of available antibodies that are both specific for anxA1 and bind the N-terminal–truncated form of anxA1 that has previously been identified in tumor vasculature. To study the vascular expression pattern of anxA1 in non–small-cell lung carcinoma (NSCLC), we isolated an antibody capable of binding N-terminal–truncated anxA127-346 and employed it in immunohistochemical studies of human lung specimens. Lung tumor specimens evaluated with this antibody revealed vascular (endothelial) anxA1 expression in five of eight tumor samples studied, but no vascular anxA1 expression was observed in normal lung tissue. Tumor microarray analysis further demonstrated positive vascular staining for anxA1 in 30 of 80 NSCLC samples, and positive staining of neoplastic cells was observed in 54 of 80 samples. No correlation was observed between vascular and parenchymal anxA1 expression. Two rodent tumor models, B16-F10 and Py230, were determined to have upregulated anxA1 expression in the intratumoral vasculature. These data validate anxA1 as a potential vascular anti-tumor target in a subset of human lung tumors and identify rodent models which demonstrate anxA1 expression in tumor vasculature.
- 4 June 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (6) , e0234268
Open AccessUpregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models
Annexin A1 (anxA1) is an immunomodulatory protein that has been proposed as a tumor vascular target for antitumor biologic agents, yet to date the vascular expression of anxA1 in specific tumor indications has not been systematically assessed. Attempts to evaluate vascular anxA1 expression by immunohistochemistry are complicated by a lack of available antibodies that are both specific for anxA1 and bind the N-terminal–truncated form of anxA1 that has previously been identified in tumor vasculature. To study the vascular expression pattern of anxA1 in non–small-cell lung carcinoma (NSCLC), we isolated an antibody capable of binding N-terminal–truncated anxA127-346 and employed it in immunohistochemical studies of human lung specimens. Lung tumor specimens evaluated with this antibody revealed vascular (endothelial) anxA1 expression in five of eight tumor samples studied, but no vascular anxA1 expression was observed in normal lung tissue. Tumor microarray analysis further demonstrated positive vascular staining for anxA1 in 30 of 80 NSCLC samples, and positive staining of neoplastic cells was observed in 54 of 80 samples. No correlation was observed between vascular and parenchymal anxA1 expression. Two rodent tumor models, B16-F10 and Py230, were determined to have upregulated anxA1 expression in the intratumoral vasculature. These data validate anxA1 as a potential vascular anti-tumor target in a subset of human lung tumors and identify rodent models which demonstrate anxA1 expression in tumor vasculature.
- 10 March 2020
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 15 (4) , 830-836
Engineering Caveolae-Targeted Lipid Nanoparticles To Deliver mRNA to the Lungs
Efficacious use of therapeutic gene delivery via nanoparticles is hampered by the challenges associated with targeted delivery to tissues of interest. Systemic administration of lipid nanoparticle (LNP)-encapsulated mRNA leads to a protein expressed predominantly in the liver and spleen. Here, LNP encapsulating mRNA was covalently conjugated to an antibody, specifically binding plasmalemma vesicle-associated protein (PV1) as a means to target lung tissue. Systemic administration of PV1-targeted LNPs demonstrated significantly increased delivery of mRNA to the lungs and a 40-fold improvement in protein expression in the lungs compared with control LNPs. We also investigated the effect of LNP size to determine optimal tissue distribution and transfection. Larger size PV1-targeted LNPs not only have the elasticity to target the PV1 expressed in the caveolae but also enable robust mRNA expression in the lungs. Targeted delivery of mRNA to the lungs is a promising approach in the treatment of lung diseases.
- 10 March 2020
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 15 (4) , 830-836
Engineering Caveolae-Targeted Lipid Nanoparticles To Deliver mRNA to the Lungs
Efficacious use of therapeutic gene delivery via nanoparticles is hampered by the challenges associated with targeted delivery to tissues of interest. Systemic administration of lipid nanoparticle (LNP)-encapsulated mRNA leads to a protein expressed predominantly in the liver and spleen. Here, LNP encapsulating mRNA was covalently conjugated to an antibody, specifically binding plasmalemma vesicle-associated protein (PV1) as a means to target lung tissue. Systemic administration of PV1-targeted LNPs demonstrated significantly increased delivery of mRNA to the lungs and a 40-fold improvement in protein expression in the lungs compared with control LNPs. We also investigated the effect of LNP size to determine optimal tissue distribution and transfection. Larger size PV1-targeted LNPs not only have the elasticity to target the PV1 expressed in the caveolae but also enable robust mRNA expression in the lungs. Targeted delivery of mRNA to the lungs is a promising approach in the treatment of lung diseases.
- 16 December 2019
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (2) , 507-516
Antibody Fragment F(ab′)2 Targeting Caveolae-Associated Protein PV1 for Selective Kidney Targeting and Retention
Targeted strategies to deliver and retain drugs to kidneys are needed to improve drug accumulation and efficacy in a myriad of kidney diseases. These drug delivery systems show potential for improving the therapeutic windows of drugs acting in the kidney. Biodistribution of antibody-based therapeutics in vivo is governed by several factors including binding affinity, size and valency. Investigations of how the biophysical and biochemical properties of biologics enable them to overcome biological barriers and reach kidneys are therefore of interest. Although renal accumulation of antibody fragments in cancer diagnostics and treatment has been observed, reports on effective delivery of antibody fragments to the kidneys remain scarce. Previously we demonstrate that targeting plasmalemma vesicle-associated protein (PV1), a caveolae-associated protein, can promote accumulation of antibody in both the lungs and the kidneys. Here, by fine-tuning the binding affinity of an antibody toward PV1, we observe that the anti-PV1 antibody with reduced binding affinity lost the capability for kidney targeting while retaining the lung targeting activity, suggesting binding affinity is a critical factor for kidney targeting of the anti-PV1 antibody. We next use the antibody fragment F(ab′)2 targeting PV1 to assess the dual effects of rapid kidney filtration and PV1 targeting on kidney selective targeting. Ex vivo fluorescence imaging results demonstrated that, after rapidly accumulating in kidneys at 4 hours, PV1-targeted F(ab′)2 was continually retained in kidney at 24 hours, whereas the isotype control F(ab′)2 underwent urinary elimination with significantly reduced signaling in kidney. Confocal imaging studies confirmed the localization of PV1 targeted F(ab′)2 in kidney. In addition, monovalent antibody fragment (Fab-C4) lost the capability for kidney homing, indicating that the binding avidity of anti-PV1 F(ab′)2 is important for kidney targeting. Our findings suggest that PV1-targeted F(ab′)2 might be useful as a drug carrier for renal targeting and highlight the importance of affinity optimization for tissue targeting antibodies.
- 16 December 2019
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (2) , 507-516
Antibody Fragment F(ab′)2 Targeting Caveolae-Associated Protein PV1 for Selective Kidney Targeting and Retention
Targeted strategies to deliver and retain drugs to kidneys are needed to improve drug accumulation and efficacy in a myriad of kidney diseases. These drug delivery systems show potential for improving the therapeutic windows of drugs acting in the kidney. Biodistribution of antibody-based therapeutics in vivo is governed by several factors including binding affinity, size and valency. Investigations of how the biophysical and biochemical properties of biologics enable them to overcome biological barriers and reach kidneys are therefore of interest. Although renal accumulation of antibody fragments in cancer diagnostics and treatment has been observed, reports on effective delivery of antibody fragments to the kidneys remain scarce. Previously we demonstrate that targeting plasmalemma vesicle-associated protein (PV1), a caveolae-associated protein, can promote accumulation of antibody in both the lungs and the kidneys. Here, by fine-tuning the binding affinity of an antibody toward PV1, we observe that the anti-PV1 antibody with reduced binding affinity lost the capability for kidney targeting while retaining the lung targeting activity, suggesting binding affinity is a critical factor for kidney targeting of the anti-PV1 antibody. We next use the antibody fragment F(ab′)2 targeting PV1 to assess the dual effects of rapid kidney filtration and PV1 targeting on kidney selective targeting. Ex vivo fluorescence imaging results demonstrated that, after rapidly accumulating in kidneys at 4 hours, PV1-targeted F(ab′)2 was continually retained in kidney at 24 hours, whereas the isotype control F(ab′)2 underwent urinary elimination with significantly reduced signaling in kidney. Confocal imaging studies confirmed the localization of PV1 targeted F(ab′)2 in kidney. In addition, monovalent antibody fragment (Fab-C4) lost the capability for kidney homing, indicating that the binding avidity of anti-PV1 F(ab′)2 is important for kidney targeting. Our findings suggest that PV1-targeted F(ab′)2 might be useful as a drug carrier for renal targeting and highlight the importance of affinity optimization for tissue targeting antibodies.
- Open Access
- 29 September 2019
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 21 (1) , 72-80
Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies
CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.
- 29 September 2019
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 21 (1) , 72-80
Open AccessIdentification of anti-CD16a single domain antibodies and their application in bispecific antibodies
CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.
- 26 March 2019
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 30 (4) , 1232-1243
Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension
Despite some clinical success with antibody-drug conjugates (ADCs) in patients with solid tumors and hematological malignancies, improvements in ADC design are still desirable due to the narrow therapeutic window of these compounds. Tumor-targeting antibody fragments have distinct advantages over monoclonal antibodies, including more rapid tumor accumulation and enhanced penetration, but are subject to rapid clearance. Half-life extension technologies such as PEGylation and albumin-binding domains (ABDs) have been widely used to improve the pharmacokinetics of many different types of biologics. PEGylation improves pharmacokinetics by increasing hydrodynamic size to reduce renal clearance, whereas ABDs extend half-life via FcRn-mediated recycling. In this study, we used an anti-oncofetal antigen 5T4 diabody conjugated with a highly potent cytotoxic pyrrolobenzodiazepine (PBD) warhead to assess and compare the effects of PEGylation and albumin binding on the in vivo efficacy of antibody fragment drug conjugates. Conjugation of 2× PEG20K to a diabody improved half-life from 40 min to 33 h, and an ABD-diabody fusion protein exhibited a half-life of 45 h in mice. In a xenograft model of breast cancer MDA-MB-436, the ABD-diabody-PBD showed greater tumor growth suppression and better tolerability than either PEG-diabody-PBD or diabody-PBD. These results suggest that the mechanism of half-life extension is an important consideration for designing cytotoxic antitumor agents.
- 26 March 2019
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 30 (4) , 1232-1243
Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension
Despite some clinical success with antibody-drug conjugates (ADCs) in patients with solid tumors and hematological malignancies, improvements in ADC design are still desirable due to the narrow therapeutic window of these compounds. Tumor-targeting antibody fragments have distinct advantages over monoclonal antibodies, including more rapid tumor accumulation and enhanced penetration, but are subject to rapid clearance. Half-life extension technologies such as PEGylation and albumin-binding domains (ABDs) have been widely used to improve the pharmacokinetics of many different types of biologics. PEGylation improves pharmacokinetics by increasing hydrodynamic size to reduce renal clearance, whereas ABDs extend half-life via FcRn-mediated recycling. In this study, we used an anti-oncofetal antigen 5T4 diabody conjugated with a highly potent cytotoxic pyrrolobenzodiazepine (PBD) warhead to assess and compare the effects of PEGylation and albumin binding on the in vivo efficacy of antibody fragment drug conjugates. Conjugation of 2× PEG20K to a diabody improved half-life from 40 min to 33 h, and an ABD-diabody fusion protein exhibited a half-life of 45 h in mice. In a xenograft model of breast cancer MDA-MB-436, the ABD-diabody-PBD showed greater tumor growth suppression and better tolerability than either PEG-diabody-PBD or diabody-PBD. These results suggest that the mechanism of half-life extension is an important consideration for designing cytotoxic antitumor agents.
- 1 June 2018
- Published by Elsevier in Journal of Controlled Release
- Vol. 279, 126-135
Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport
- 1 June 2018
- Published by Elsevier in Journal of Controlled Release
- Vol. 279, 126-135
Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport
- Open Access
- 28 January 2016
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 17 (4) , 364-370
A novel bispecific antibody, BiSS, with potent anti-cancer activities
One of the most active fields in cancer immunotherapy is the study of bispecific antibodies, which engage immune cells to kill cancer cells. However, a variety of issues are associated with most of current bispecific antibody formats. In this study, we present a novel bispecific antibody, BiSS (Bispecific antibody with Single domain, Single domain antibodies), which was constructed by linking 2 single domain antibodies, anti-CEA and anti-CD16, in tandem. Unlike most other bispecific antibodies, the BiSS antibody can be expressed and purified from E.coli in large quantities. By recruiting natural killer cells (NK cells) to CEA-positive cancer cells, BiSS led to cancer cell death in vitro. In xenograft models, the BiSS protein blocked cancer progression. The data suggested that the single domain-based bispecific antibody BiSS was functional and can be potentially applied to a broad range of immunotherapies.
- 28 January 2016
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 17 (4) , 364-370
Open AccessA novel bispecific antibody, BiSS, with potent anti-cancer activities
One of the most active fields in cancer immunotherapy is the study of bispecific antibodies, which engage immune cells to kill cancer cells. However, a variety of issues are associated with most of current bispecific antibody formats. In this study, we present a novel bispecific antibody, BiSS (Bispecific antibody with Single domain, Single domain antibodies), which was constructed by linking 2 single domain antibodies, anti-CEA and anti-CD16, in tandem. Unlike most other bispecific antibodies, the BiSS antibody can be expressed and purified from E.coli in large quantities. By recruiting natural killer cells (NK cells) to CEA-positive cancer cells, BiSS led to cancer cell death in vitro. In xenograft models, the BiSS protein blocked cancer progression. The data suggested that the single domain-based bispecific antibody BiSS was functional and can be potentially applied to a broad range of immunotherapies.
- 12 December 2008
- Published by Wiley in Angewandte Chemie
- Vol. 120 (52) , 10333-10336
Self‐Assembly of Antibodies by Chemical Induction
- 12 December 2008
- Published by Wiley in Angewandte Chemie
- Vol. 120 (52) , 10333-10336
Self‐Assembly of Antibodies by Chemical Induction